Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Pablo Gerardo Legorreta | Founder, Chairman of the Board & CEO | -- | -- | 1965 |
| Mr. Terrance P. Coyne | Executive VP & CFO | 4.56M | -- | -- |
| Mr. George Wingate Lloyd | Executive VP of Investments & Chief Legal Officer | 4.56M | -- | 1960 |
| Mr. Christopher Hite | Vice Chairman & Executive VP | 4.56M | -- | 1968 |
| Dr. Marshall Jonathan Urist M.D., Ph.D. | Executive Vice President of Research & Investments | 4.56M | -- | 1977 |
| Mr. Arthur Richard McGivern J.D. | Executive Vice President of Investments & General Counsel | -- | -- | -- |
| Mr. Ashwin Pai M.D. | Executive Vice President of Investments | -- | -- | -- |
| Ms. Kristin Stafford | Senior VP & Chief Accounting Officer | -- | -- | 1983 |
| Mr. Eric Cornelius Schneider | Senior VP & Chief Technology Officer | -- | -- | -- |
| Dr. James Folmar Reddoch Ph.D. | Executive VP of Investments & Chief Scientific Officer | 3.4M | -- | 1971 |
Royalty Pharma plc
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Corporate Governance
Upcoming Events
May 8, 2025 at 12:30 PM UTC
Royalty Pharma plc Earnings Date
Recent Events
March 10, 2025 at 12:00 AM UTC
Dividend Date
February 21, 2025 at 12:00 AM UTC
Ex-Dividend Date
January 15, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions